Rationale, design and population baseline characteristics of the PERFORM Vascular Project : an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial / Michael G. Hennerici, Michiel L. Bots, Ian Ford, Stéphane Laurent, Pierre Jean Touboul
Purpose - PERFORM is exploring the efficacy of terutroban versus aspirin for secondary prevention in patients with a history of ischemic stroke or transient ischemic attacks (TIAs). The PERFORM Vascular Project will evaluate the effect of terutroban on progression of atherosclerosis, as assessed by change in carotid intima-media thickness (CIMT) in a subgroup of patients. - - Methods and results - The Vascular Project includes structural (CIMT, carotid plaques) and functional (carotid stiffness) vascular studies in all patients showing at least one carotid plaque at entry. Expected mean follow-up is 36 months. Primary endpoint is rate of change of CIMT. Secondary endpoints include emergent plaques and assessment of carotid stiffness. 1,100 patients are required for 90% statistical power to detect treatment-related CIMT difference of 0.025 mm. The first patient was randomized in April 2006. - - Conclusions - The PERFORM Vascular Project will investigate terutroban’s effect on vascular structure and function in patients with a history of ischemic stroke or TIAs.
|Persons:||; ; ; ;|
|Publication:||20 May 2010|
|Part of:||Cardiovascular drugs and therapy 24(2010), 2, Seite 175-180|
|Notes:||Gesehen am 12.03.2021|